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Paired blood samples collected in acid-citrate-dextrose and EDTA were compared for human immunodefi-
ciency virus (HIV) infectivity on the day of collection or after 1 day of storage at room temperature. No
significant differences between the anticoagulants were observed. Culture positivity was significantly associated
with HIV RNA viral loads for both anticoagulants.
EDTA is widely recognized as the best anticoagulant for
plasma specimens used for human immunodeficiency virus
(HIV) RNA determinations (3, 6, 8, 10), while heparin and
acid-citrate-dextrose (ACD) are usually used for obtaining
cells to be used in HIV culture (2, 4, 7, 11). Drawing two
separate tubes of blood for these two assays is an inconve-
nience and, especially in the case of children, may be limited by
a small total blood volume. In an attempt to find one antico-
agulant that could be used for both assays, we performed a
series of HIV cultures with samples from consecutive patients
enrolled in a variety of clinical trials who were having both
ACD and EDTA tubes of blood drawn for protocol-specified
HIV RNA and HIV peripheral blood mononuclear cell
(PBMC) cultures.
All patients gave informed consent for the studies, which
were approved by the Institutional Review Board for the Uni-
versity of North Carolina at Chapel Hill. A total of 105 paired
specimens were obtained. The first 50 paired specimens were
obtained from 17 individuals and cultured within 4 h of blood
collection (cohort 1). Concerns over the possible fragility of
cells stored overnight in EDTA prompted a second round of
testing. As a result, 55 paired specimens from 43 individuals
were cultured after an overnight, room-temperature incuba-
tion simulating shipping conditions (cohort 2). Plasma HIV
RNA from blood collected in EDTA was performed by the
Amplicor monitor assay (Roche Diagnostic Systems, Branch-
burg, N.J.), following the manufacturer’s instructions and in-
cluding Division of AIDS Virus Quality Assurance Laboratory
standards. Qualitative HIV PBMC cultures were set up from
cells isolated either from the ACD or the EDTA blood by
established techniques (11). A culture was deemed positive by
guidelines established by the AIDS Clinical Trials Group. Ba-
sically, a culture is considered positive if one of the following
three conditions is met: (i) two consecutive HIV p24 antigen
values greater than 30 pg/ml and the second value is at least
four times greater than the first value or has an optical density
of .2.0, (ii) two consecutive HIV p24 antigen values with
optical densities of .2.0, or (iii) three consecutive increasing
HIV p24 antigen values greater than 30 pg/ml, where neither
consecutive value is four times greater than the previous sam-
ple but the third value is four times greater than the first (11).
The laboratory was certified as proficient for these assays by
the Virus Quality Assurance Laboratory.
The first day that a culture had at least 30 pg of p24 antigen
per ml in the culture supernatant was recorded as the day it
became positive. For statistical purposes, negative cultures
were arbitrarily set at 25 days. Specimens with concentrations
of ,400 HIV RNA copies/ml were assigned a value of 400
copies/ml in the analysis. The McNemar’s test was used to test
the differences between the two anticoagulants’ abilities to
produce a positive culture. The t test was used to test the
difference in mean number of days before a culture became
positive. Pearson’s correlation coefficient was used to evaluate
the relationship between HIV RNA concentration and the
number of days required to obtain a positive culture.
First, we determined whether there was any difference be-
tween the two anticoagulants and their ability to culture HIV
from PBMCs. Overall concordance in culture sensitivity was
88% (92 of 105 pairs were concordant). Seventy-two pairs were
positive in both cultures, and 20 were negative in both cultures.
Of the 13 discordant pairs, seven ACD-collected PBMC cul-
tures were positive and six EDTA-collected PBMC cultures
were positive. Overall, 75% of the cultures were positive, and
it took about 6.7 days for the p24 antigen concentration to
reach 30 pg/ml for those cultures which actually became pos-
itive (Table 1). Negative cultures were not used in the analysis
of days to positive culture.
We next investigated differences between the anticoagulants
for when cells are cultured soon after collection compared with
waiting 20 to 24 h, which frequently occurs when blood is
shipped to a central laboratory for culture. We saw no differ-
ence either in sensitivity or in the number of days it took for a
culture to turn positive (Table 1). Surprisingly, however, only
62 to 66% of the fresh cultures (cohort 1) were positive, com-
pared with 82 to 87% of the specimens stored overnight (co-
hort 2), and it took an average of 8.6 to 8.9 days for the fresh
specimens to first turn positive, compared with 5.0 to 5.6 days
for the overnight specimens.
The answer to this apparent paradox was found in the
plasma HIV RNA values of the specimens and the way in
which the study was conducted. The specimens for cohort 1
were largely obtained from subjects already enrolled in clinical
trials while the other 55 subjects were primarily selected from
patients being screened or at the baseline for other clinical
trials. The average viral load of the first 50 patients was 17,784
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copies/ml (median, 1,739 copies/ml) and ranged from ,400 to
291,269 copies/ml compared with an average of 336,164 cop-
ies/ml (median, 169,946 copies/ml) for cohort 2 patients
(range, ,400 to 2,527,778 copies/ml).
We paired specimens from cohort 1 and cohort 2 based on
HIV type 1 (HIV-1) RNA levels (within 0.2 log) and reana-
lyzed the length of time it took for a culture to become positive
(Table 2). A total of 27 pairs were compared, with viral loads
ranging from ,400 to 291,269 copies/ml. Mean viral loads were
23,448 HIV-1 RNA copies/ml for the fresh specimens (cohort
1A) and 24,737 copies/ml for the overnight specimens (cohort
2A). The mean numbers of days for a culture to become
positive were 9.1 and 9.6 for ACD and EDTA, respectively, in
the fresh cultures. In the case of both anticoagulants, 66.7% of
the cultures in this group were positive. For the 27 overnight
cultures, 74% of the ACD specimens produced a positive cul-
ture in an average of 7.8 days while 66.7% of the EDTA
specimens became positive on average by 6.3 days.
We found that the sensitivity of the HIV PBMC cultures was
significantly associated with plasma viral loads (P , 0.0001).
Only 26% (13 of 50) of specimens with plasma HIV RNA
concentrations of ,400 copies/ml yielded a positive culture,
compared with 79% (38 of 48) of specimens with viral loads
between 400 and 5,000 HIV RNA copies/ml, 89% (39 of 44) of
specimens with viral loads between 5,000 and 100,000 copies/
ml, and 99% (67 of 68) of specimens with viral loads greater
than 100,000 copies/ml (Fig. 1). There was a weak inverse
relationship between RNA concentration and number of days
to a positive culture (r 5 20.33, P , 0.0001). Nine of the 13
specimens for which discrepant culture results were obtained
had low viral loads that were less than 2,000 copies/ml.
It thus appears that EDTA can be used as an anticoagulant
when setting up HIV PBMC cultures. Other investigators have
compared EDTA with heparin in HIV whole-blood cultures,
but results have been mixed. Some reported higher isolation
rates with EDTA (1), some obtained better results with hep-
arin (12), while others found no difference between the two
anticoagulants (5). The cultures performed in this study em-




Cohort 1 (n 5 50) Avg time between blood draw and culture 4 h 4 h
Sensitivity [no. positive (%)] 31 (62) 33 (66)




Cohort 2 (n 5 55) Avg time between blood draw and culture 22 h 22 h
Sensitivity [no. positive (%)] 48 (87) 45 (82)




Total (n 5 105) Sensitivity [no. positive (%)] 79 (75) 78 (74)




a The two patient cohorts are not directly comparable since viral loads were, in general, much higher in cohort 2.
b ND, not done.





Cohort 1A (n 5 27) Avg time between blood draw and culture 4 h 4 h
Sensitivity [no. positive (%)] 18 (66.7) 18 (66.7)




Cohort 2A (n 5 27) Avg time between blood draw and culture 22 h 22 h
Sensitivity [no. positive (%)] 20 (74.1) 18 (66.7)




a ND, not done.
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ployed PBMCs isolated on Ficoll-Hypaque gradients and
washed extensively prior to culture, which would remove most,
if not all, of the anticoagulant. In our study, we found no
significant differences between the two anticoagulants as mea-
sured by the sensitivity of the culture assays (ability to culture
HIV from the specimen) or in the number of days it took a
culture to become positive. Similarly, in a comparison of ACD-
and EDTA-collected blood samples and cytomegalovirus in-
fectivity and pp65 antigenemia assays, no significant differ-
ences between the two anticoagulants were observed (9).
Not surprisingly, we observed an association in the ability to
culture HIV from PBMCs and the plasma viral load. This had
been reported by others (M. B. Bouzas, I. Zapiola, J. Waisman,
and G. R. Muchinik, Intern. Conf. AIDS, abstr. 42176, 1998).
However, it was somewhat surprising to find that 26% of spec-
imens with viral loads of ,400 copies/ml had recoverable in-
fectious virus. In a substudy of ACTG 320, approximately 44%
of PBMC cultures from patients with viral loads of ,500 cop-
ies/ml were positive (L. Demeter, M. Hughes, M. Fischl, J.
Grimes, R. Bosch, K. Squires, and S. Hammer for the ACTG
320 Study Team, 5th Conf. Retrovir. Opportunistic Infect.,
abstr. 509, 1998). Using a cutoff of 500 copies/ml in our data
set, we find that 41% of patients have recoverable virus.
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FIG. 1. Sensitivity of HIV PBMC cultures according to log10 HIV RNA
plasma viral loads with ACD or EDTA as the anticoagulant.
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